NCT05669287 is a NA clinical trial of CT Perfusion in PDAC - Pancreatic Ductal Adenocarcinoma, sponsored by Radboud University Medical Center.

Who is sponsoring NCT05669287?

NCT05669287 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT05669287?

Interventions in NCT05669287: CT Perfusion.

What condition does NCT05669287 study?

NCT05669287 studies PDAC - Pancreatic Ductal Adenocarcinoma.

Is NCT05669287 still recruiting?

NCT05669287 is currently status unknown. Last updated 3 May 2023.

Last reviewed 2023-05-03 · How we verify

NCT05669287

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics

Status unknown NA Last updated 3 May 2023

What this trial tests

NA trial testing CT Perfusion in PDAC - Pancreatic Ductal Adenocarcinoma in 125 participants. Status unknown.

Timeline

22 December 2017

Primary endpoint
31 December 2022

1 June 2023

Quick facts

Lead sponsor	Radboud University Medical Center
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	125
Start date	22 December 2017
Primary completion	31 December 2022
Estimated completion	1 June 2023
Sites	1 location across Netherlands

Drugs / interventions tested

CT Perfusion

Conditions studied

PDAC - Pancreatic Ductal Adenocarcinoma — all drugs for PDAC - Pancreatic Ductal Adenocarcinoma →

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with PDAC - Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

With CT-perfusion(CTP) it is possible to visualize the enhancement pattern of the tumor. The perfusion CT, interleaved with a routine contrast enhanced CT (CECT) will be performed at diagnosis in all patients (goal: n=125 patients) and at the first follow-up at 3 months in patients treated with systemic therapy (goal: n=50 patients). Also, the histopathology will be collected for resected tumors to perform histopathology analysis. CTP parameters will be correlated to immunohistological findings and clinical outcome. The main goal of the study is to create an AI-assisted method to classify patients with a vascular phenotype of pancreatic ductal adenocarcinoma (PDAC). The investigators expect that this phenotype can be used to predict overall survival and chemotherapy response.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Automated Quantitative Analysis of CT Perfusion to Classify Vascular Phenotypes of Pancreatic Ductal Adenocarcinoma.
Perik T, Alves N, Hermans JJ, Huisman H. · · 2024 · cited 1× · PMID 38339328 · DOI 10.3390/cancers16030577

Verify or expand the search:

Other trials of CT Perfusion

Trials testing the same drug.

NCT07099599 — Image Detection of Impaired Microcirculatory Reperfusion · recruiting
NCT04323020 — CT Perfusion (CTP) for Assessment of Poor Neurological Outcome in Comatose Cardiac Arrest Patients · NA · completed
NCT04318665 — Early Diagnosis of Mortality Using Admission CT Perfusion in Severe Traumatic Brain Injury Patients (ACT-TBI Study) · NA · completed
NCT01923922 — CT Perfusion in the Prognostication of Cerebral High Grade Glioma · NA · completed

Other recruiting trials for PDAC - Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

NCT07252232 — Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) · Phase 3 · recruiting
NCT07243262 — Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) · recruiting
NCT07262957 — Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Inc · Phase 4 · recruiting
NCT07117045 — Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer · recruiting
NCT06122896 — Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals · EARLY_PHASE1 · recruiting

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05669287 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 3 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05669287.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing